In line with this, a bibliometric analysis conducted by Xiong et al. (2022) on immunotherapy and biotherapy for IBD revealed that anti-TNF therapy, specifically, infliximab, has been a major research area for the last decade. The gene discussed is TNF; the disease is inflammatory bowel disease.